OTCMKTS:NURPF Neuren Pharmaceuticals (NURPF) Stock Price, News & Analysis → Kiss of death from Joe Biden (From Porter & Company) (Ad) Free NURPF Stock Alerts C$14.00 +0.50 (+3.70%) (As of 05/31/2024 ET) Add Compare Share Share Today's RangeC$14.00▼C$14.0050-Day RangeC$12.51▼C$13.9152-Week RangeC$6.17▼C$17.21Volume5,023 shsAverage Volume4,710 shsMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisAnalyst ForecastsChartHeadlinesShort InterestStock AnalysisAnalyst ForecastsChartHeadlinesShort Interest Get Neuren Pharmaceuticals alerts: Email Address Ad The Freeport SocietyBiden Nomination CANCELED?The Hill just published that Joe Biden has received enough delegates to…“clinch the Democratic presidential nomination and all but guaranteeing he will face off against former President Trump again in November.” Why is he all BUT guaranteed the Democratic nomination, in their words?I believe I have the terrifying answer right here. About Neuren PharmaceuticalsNeuren Pharmaceuticals Limited, a biopharmaceutical company, develops drugs for the treatment of neurological disorders. It develops and commercializes DAYBUE (trofinetide), which has been registered to treat Rett syndrome in adults and pediatric patients 2 years of age and older, as well as in Phase 2 clinical trial to treat Fragile X syndrome. The company also develops NNZ-2591, which has completed Phase 2 clinical trial for the treatment of Phelan-McDermid, and in Phase 2 clinical trial for the treatment of Angelman, Pitt Hopkins, and Prader-Will syndromes. In addition, it provides development services; and holds loan funded shares. The company was incorporated in 2001 and is based in Camberwell, Australia.Read More NURPF Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart NURPF Stock News HeadlinesMay 22, 2024 | investing.comNeuren Pharmaceuticals Ltd (NEU)March 1, 2024 | finance.yahoo.comAre Robust Financials Driving The Recent Rally In Neuren Pharmaceuticals Limited's (ASX:NEU) Stock?February 15, 2024 | afr.com‘Total flop’: Neuren Pharma sinks 15pc on short-seller reportJanuary 23, 2024 | wsj.comNeuren Pharmaceuticals Ltd.December 29, 2023 | markets.businessinsider.comJefferies Reaffirms Their Buy Rating on Neuren Pharmaceuticals Limited (NURPF)December 18, 2023 | afr.comBiotech sensation Neuren rallies to record on clinical trial resultsDecember 18, 2023 | markets.businessinsider.comNeuren Pharma Announces Positive Results From Phase 2 Study Of NNZ-2591 In Phelan-McDermid SyndromeDecember 18, 2023 | finance.yahoo.comNeuren Phase 2 trial shows significant improvements in Phelan-McDermid syndromeAugust 31, 2023 | markets.businessinsider.comWilsons Sticks to Its Buy Rating for Neuren Pharmaceuticals Limited (NURPF)July 14, 2023 | afr.comNeuren shares soar on deal to take Rett syndrome drug to the worldJuly 14, 2023 | markets.businessinsider.comWilsons Sticks to Their Buy Rating for Neuren Pharmaceuticals Limited (NURPF)July 13, 2023 | fool.com.auWhy is the Neuren Pharmaceuticals share price rocketing 26% on Friday?April 22, 2023 | msn.comWILSONS Maintains Neuren Pharmaceuticals (ASX:NEU) Overweight RecommendationMarch 17, 2023 | msn.comScoPo’s Powerplays: ASX health stocks drop as Neuren surges 60% on US FDA approvalMarch 12, 2023 | msn.comBoost for ASX healthcare sector as Neuren gets US FDA approval for drug to treats Rett’s syndromeMarch 3, 2023 | finance.yahoo.comNeuren Pharmaceuticals Limited (NURPF)January 11, 2023 | finance.yahoo.comBreakeven Is Near for Neuren Pharmaceuticals Limited (ASX:NEU)See More Headlines Receive NURPF Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Neuren Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Industry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolOTCMKTS:NURPF CUSIPN/A CIKN/A Webwww.neurenpharma.com Phone(139) 092-0480FaxN/AEmployeesN/AYear FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable BetaN/A 7 Stocks to Buy And Hold ForeverClick the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free Report Key ExecutivesMr. Jonathan Charles Pilcher A.C.A.ACA, B.Sc., BSc (Hons), F.C.A., CEO, MD & Executive DirectorMs. Lauren Frazer C.A.CFO & Company SecretaryMr. Lawrence Glass BA (Biology)Chief Science OfficerMr. Gerry ZhaoVice President of Corporate DevelopmentDr. Liza A. Squires M.D.Chief Medical OfficerKey Competitors180 Life SciencesNASDAQ:ATNFW3SBioOTCMKTS:TRSBF60 Degrees PharmaceuticalsNASDAQ:SXTPWAbcamOTCMKTS:ABCZFAdociaOTCMKTS:ADOIFView All Competitors NURPF Stock Analysis - Frequently Asked Questions Should I buy or sell Neuren Pharmaceuticals stock right now? 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Neuren Pharmaceuticals in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" NURPF shares. View NURPF analyst ratings or view top-rated stocks. How have NURPF shares performed in 2024? Neuren Pharmaceuticals' stock was trading at C$16.98 at the beginning of 2024. Since then, NURPF shares have decreased by 17.6% and is now trading at C$14.00. View the best growth stocks for 2024 here. How do I buy shares of Neuren Pharmaceuticals? Shares of NURPF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (OTCMKTS:NURPF) was last updated on 6/2/2024 by MarketBeat.com Staff From Our PartnersBiden Nomination CANCELED?The Freeport SocietyWarren Buffett, Jeff Bezos, Michael Bloomberg, & 48 Members of Congress Are Buying ONE Sector…InvestorPlaceTrump’s Gift Could Unleash $51 Billion in New WealthWealthpin ProBiden replacement revealed?Paradigm PressShocking: One AI startup's revenue could surge 4,735%Manward PressNvidia has Apple and Microsoft within striking rangeWeiss RatingsDon’t buy a single NVIDIA share before you see this...Behind the MarketsExposed: 10 CENT Crypto to Explode May 20th?True Market Insiders Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Neuren Pharmaceuticals Limited Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
